Browse by author
Lookup NU author(s): Dr Yvette DrewORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.
Author(s): Drew Y
Publication type: Review
Publication status: Published
Journal: British Journal of Cancer
Online publication date: 15/12/2015
Acceptance date: 01/01/1900
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
Publisher: NATURE PUBLISHING GROUP